BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Flu concerns grow in US as UK sees more cases among kids - 2Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- 3The Best 15 Applications for Efficiency and Association
- 4Native Americans had dice and games of probability long before other cultures, study finds
- 55 Must-Attempt Fascinating Dishes from Around the World
- Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- Instructions to Discuss Successfully with Your Auto Collision Lawyer
- Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover
- The Most Compelling Innovation Advancements Somewhat recently
- Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- 4 Excellent Remote Headphones of 2024
- The Way to Monetary Health: Individual budget Change
- At least 18 Palestinians killed in latest clashes in Gaza
- BravoCon 2025: How to watch, full schedule and lineup, where to stream free and more
